Cellnovo Targets 2018 Launch Of Insulin Micropump With Artificial Pancreas Tech
Cellnovo has signed a commercial license agreement with digital health firm TypeZero to integrate its artificial pancreas software technology into Cellnovo’s digitally connected insulin patch pump. The integrated product is expected to launch in 2018.
You may also be interested in...
Diabetes companies Senseonics and TypeZero Technologies have signed a research and development licensing agreement to develop an artificial pancreas.
Cellnovo is integrating Roche’s Accu-Chek blood glucose monitoring platform into the latest version of its mobile, all-in-one diabetes management system. The Swiss drug and diagnostics giant’s BGM technology will replace Johnson & Johnson’s LifeScan OneTouch Vita which Cellnovo has been using until now.
Quanta Dialysis has signed an agreement with B. Braun to provide support services to Quanta’s patients in the UK. The hemodialysis firm launched its compact hemodialysis device SC+ on the market at the beginning of the year.